Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Meta Expands AI Training With Employee Activity Tracking Tools 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 29, 2016 -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that David Domzalski, President, will provide a corporate overview and business update at the 36th Annual Cowen & Co. Healthcare Conference, taking place in Boston, Massachusetts March 7-8, 2016.
Presentation Details:
| Title: | 36th Annual Cowen & Company Healthcare Conference |
| Date: | March 7 |
| Time: | 3:20pm Eastern Time |
| Location: | The Marriott Copley Hotel |
| Webcast: | http://wsw.com/webcast/cowen30/fomx |
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX 103 for the treatment of rosacea, and FDX104, our doxycycline foam for the management of acne-like rash, induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Prestium. For more information, please visit www.foamixpharma.com.
Contact: Dorit Hayon, BD Foam Pharmaceuticals, Ltd. +972-8-9316233 [email protected]
